Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

Apte wins Elkeles Prize for outstanding scientist in field of medicine

Ben-Gurion University of the Negev (BGU) Professor Ron N. Apte has been awarded the 2010 Samuel and Paula Elkeles Prize for Outstanding Scientist in the Field of Medicine.

9 Aug 2010

EpiCept second-quarter net loss decreases to $4.9 million

EpiCept Corporation today announced operating and financial results for the three and six months ended June 30, 2010, and provided an update with respect to the Company's key business initiatives.

7 Aug 2010

FDA designates XOMA 052 orphan drug for Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.

5 Aug 2010

Arcelis immunotherapy effective in treating autoimmune diseases: Study

Argos Therapeutics today announced that its Arcelis immunotherapy targeted at diabetes demonstrated potential for preventing and treating the disease in non-obese diabetic (NOD) mice, according to a peer-reviewed article published in Molecular Therapy.

4 Aug 2010

ZymoGenetics second-quarter net loss declines to $3.8 million

ZymoGenetics, Inc. today reported substantially improved financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the company's net loss declined to $3.8 million, or $0.04 per share, a $23.2 million improvement from the $27.0 million loss, or $0.39 per share, reported for the second quarter of 2009. The improvement resulted from higher revenues as well as reduced operating expenses.

4 Aug 2010

Alphavirus vaccine blocks tumor growth in advanced cancer: Research

An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.

3 Aug 2010

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Today, Formatech, Inc. announced that it has selected Femta's FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta's upcoming clinical trials.

31 Jul 2010

EMA recommends orphan medicinal product designation for XOMA 052 in treatment of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medicines Agency (EMA) has adopted a positive opinion and recommends the granting of orphan medicinal product designation for XOMA 052, an antibody to interleukin-1 beta, for the treatment of Behcet's disease. Positive opinions are submitted to the European Commission for decision and are generally adopted within 30 days of receipt.

29 Jul 2010

Researchers examine why some obese people become diabetic while others do not

Why some obese people go on to become diabetic while others do not. It is common to find obese people - even morbidly obese people - who are healthier than their condition would normally allow.

29 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

Susceptibility to Behcet's disease associated with genes involved in body's immune response

Researchers with the National Institutes of Health have found susceptibility to Behcet's disease, a painful, inflammatory condition, to be associated with genes involved in the body's immune response.

14 Jul 2010

LSUHSC Professor awarded $2.1M grant to determine role of PCP

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to determine the role and identify which T-helper cells fight the opportunistic infection, Pneumocystis carinii pneumonia, which can be a complication of HIV/AIDS.

14 Jul 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

Antibody-producing B cells promote atherosclerosis: Study

Antibody-producing B cells promote atherosclerosis in mice, according to a study to be published online on July 5th in the Journal of Experimental Medicine (www.jem.org) These findings came as a surprise, as prior studies had suggested that B cells help protect against the disease.

6 Jul 2010

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

1 Jul 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

Preliminary findings show RA drug reduces brain damage in stroke patients

A drug used to treat rheumatoid arthritis also reduces the damage a stroke inflicts on the brain according to lab research and preliminary findings from a clinical trial of stroke patients. The results open the door for a larger clinical study to refine the drug anakinra's use as an effective therapy for victims of stroke.

From The University of Manchester 30 Jun 2010

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

An immune cell known to cause chronic inflammation in autoimmune disorders has been identified as a possible culprit in low back pain associated with herniated discs, according to doctors at Duke University Medical Center.

29 Jun 2010

EpiCept requests FDA priority review of Ceplene NDA for AML

EpiCept Corporation announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Ceplene® (histamine dihydrochloride). EpiCept is seeking approval for Ceplene, administered concomitantly with low-dose interleukin-2 (IL-2), for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first complete remission.

29 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010